DelNS1-2019-nCoV-RBD-OPT
Appearance
From Wikipedia, the free encyclopedia
Vaccine against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Pneucolin |
Other names | DelNS1-nCoV-RBD LAIV[1] |
Routes of administration | Intranasal |
Part of a series on the |
COVID-19 pandemic |
---|
|
Medical response |
|
|
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4] It is administered as a single dose intranasal spray.[5]
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[6]
References
[edit]- ^ "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
- ^ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
- ^ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
- ^ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
- ^ Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, et al. (January 2024). "Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study". EClinicalMedicine. 67: 102374. doi:10.1016/j.eclinm.2023.102374. PMC 10758709. PMID 38169940.
- ^ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" [Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination] (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
Scholia has a profile for DelNS1-2019-nCoV-RBD-OPT (Q106522065).
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- CS1 Chinese-language sources (zh)
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles